Wang J, Lu S, Yu X, et al. - By conducting this open-label, randomized phase 3 clinical trial, tislelizumab plus chemotherapy was compared with chemotherapy alone, in terms of efficacy and safety/tolerability, when administered as first-line treatment for patients suffering from advanced squamous non–small-cell lung cancer (sq-NSCLC). The participants were treatment-naive, with histologically confirmed stage IIIB/IV of sq-NSCLC. It was found that irrespective of programmed cell death 1 ligand 1 expression, significantly prolonged independent review committee (IRC)-assessed progression-free survival, higher IRC-assessed objective response rates, as well as a manageable safety/tolerability profile were obtained as a result of adding tislelizumab to chemotherapy for treating patients with advanced sq-NSCLC in this study.